B Krishnakumar, head- equity research at fundsindia.com told CNBC-TV18, "Divis Laboratories looks pretty good. Lot of pharma stocks have been attracting buying interest including Aurobindo Pharma and Suven Life Sciences. We are positive on Divis Labs with stoploss of Rs 1090 and we are looking at Rs 1400 and beyond in the stock."
On December 20, 2013 Divis Laboratories ended at Rs 1,183.60, up Rs 5.20, or 0.44 percent.
The company's trailing 12-month (TTM) EPS was at Rs 32.85 per share. (Sep, 2013). The stock's price-to-earnings (P/E) ratio was 35.92. The latest book value of the company is Rs 192.36 per share. At current value, the price-to-book value of the company was 6.13. The dividend yield of the company was 1.27 percent.
Disclosure: He does not have any exposure in the stock but he might have discussed the stock with his clients.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
